Please login to the form below

Not currently logged in
Email:
Password:

Jonathan Emms

This page shows the latest Jonathan Emms news and features for those working in and with pharma, biotech and healthcare.

Pfizer UK appoints Erik Nordkamp as new managing director

Pfizer UK appoints Erik Nordkamp as new managing director

He takes over from Jonathan Emms who moves to a global role within the firm. ... Nordkamp will take over from Jonathan Emms, who becomes global marketing lead for Pfizer's global established pharmaceutical (GEP) business.

Latest news

  • NHS 'not driving' health innovation NHS 'not driving' health innovation

    Also speaking at the London event, which was organised by comms agency Hanover, was ABPI president and Pfizer UK's managing director Jonathan Emms. ... Emms also called for the government's science budget to be “sustained and ring fenced” after David

  • Pfizer slams UK drug pricing plan Pfizer slams UK drug pricing plan

    This was not enough for Jonathan Emms, Pfizer's UK managing director, who said: “NICE must be given a new mandate, one that makes it a beacon for innovation, helping to

  • Pfizer's Xalkori 'not good value for money', says NICE Pfizer's Xalkori 'not good value for money', says NICE

    Pfizer UK managing director Jonathan Emms pre-empted the final NICE guidance for Xalkori with an editorial at the end of last month which slammed the tools used by the agency ... wrote Emms in the opinion piece.

  • NICE questions cost of medicines development NICE questions cost of medicines development

    director Jonathan Emms that it now takes £1.2bn to bring a new medicine to patients and companies should be rewarded appropriately through the price of their drugs in order to ... The European regulatory process was able to manage the uncertainty caused

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

  • ABPI names Amgen’s UK head as president ABPI names Amgen’s UK head as president

    John Kearney replaces Pfizer’s Jonathan Emms. The Association of the British Pharmaceutical Industry (ABPI) has appointed John Kearney as its new president, effective from April 24. ... He replaces Jonathan Emms, who is stepping down as president as he

  • Pfizer’s Emms takes up ABPI presidency Pfizer’s Emms takes up ABPI presidency

    Pfizer's UK managing director Jonathan Emms has taken up the role of president of the Association of the British Pharmaceutical Industry (ABPI). ... These concerns about access to new medicines were reiterated by Emms in a statement on what he hopes to

  • MSD appoints new UK head MSD appoints new UK head

    As previously announced, Khanna will also step down from his role as president of the Association of the British Pharmaceutical Industry (ABPI) to be replaced by Pfizer's Jonathan Emms.

  • Pfizer's Jonathan Emms to be ABPI president Pfizer's Jonathan Emms to be ABPI president

    Will take over from MSD's Deepak Khanna in April. Pfizer's UK managing director Jonathan Emms has been elected as the next president of the Association of the British Pharmaceutical ... Beginning his career at Glaxo, Emms joined Pfizer in 1999 and in

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics